title: Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
authors.affiliation: Cancer Immunology Unit, University College London Cancer Institute, London, UK.|The Royal Marsden NHS Foundation Trust, London, UK.
authors.forename: Andrew Js
authors.initials: AJ
authors.lastname: Furness
authors.affiliation: Cancer Immunology Unit, University College London Cancer Institute, London, UK.
authors.forename: Sergio A
authors.initials: SA
authors.lastname: Quezada
authors.affiliation: Cancer Immunology Unit, University College London Cancer Institute, London, UK.
authors.forename: Karl S
authors.initials: KS
authors.lastname: Peggs
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D060890:B7-H1 Antigen / Q000276:immunology; D054316:Biomarkers, Pharmacological / Q000378:metabolism*; D060908:CTLA-4 Antigen / Q000276:immunology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000637:transplantation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D018579:Patient Selection; D057285:Precision Medicine; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D060890:B7-H1 Antigen; D054316:Biomarkers, Pharmacological; D060908:CTLA-4 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor
keywords: CTLA-4; PD-1; heterogeneity; neoantigens